Analysts have recently shared their views on three healthcare stocks: Insulet (PODD), UnitedHealth (UNH), and Ottobock SE & Co. KGaA (OBCKF). Robert W. Baird analyst Jeff Johnson downgraded Insulet to Hold with a price target of $158.00, while the stock closed last Thursday at $137.23. Johnson, a 5-star analyst, has an average return of 9.7% and a 49.6% success rate. Despite the downgrade, Insulet maintains a Moderate Buy consensus among analysts, with a price target consensus of $172.85, suggesting a 23.8% upside.
UnitedHealth received a Buy rating and a $455.00 price target from TD Cowen analyst Ryan Langston. The stock closed last Thursday at $330.48. Langston, a 3-star analyst, covers the healthcare sector. The broader analyst consensus for UnitedHealth is a Strong Buy, with an average price target of $486.00, indicating a 38.4% potential upside.
Ottobock SE & Co. KGaA was maintained as a Buy by Jefferies analyst Henrik Paganetty, who set a price target of EUR83.00. Despite this, the stock has a Strong Buy consensus with an average price target of $73.69, which represents a -99.1% downside from current levels. Deutsche Bank also maintained a Buy rating with a EUR56.00 price target.